LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression

Wei, Yongpeng; Wang, Zhuo; Zong, Yi; Deng, Dewu; Chen, Peiqin; Lü, Junhua

doi:10.1016/j.biopha.2020.109890

Cited by 33 publications

(19 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, PVT1 is located on chromosome band 8q24.21 and is frequently co-amplified with MYC [ 30 , 194 ]. Additional miRNAs established to target FOXM1 in ovarian cancer are miR-134 [ 195 , 196 , 197 , 198 , 199 ] and miR-216b [ 200 , 201 , 202 , 203 ]. Interestingly, a recent report indicates that FOXM1 acts as a transcriptional regulator of several miRNA molecules in triple-negative breast cancer, which has a similar molecular profile to HGSC [ 204 ].…”

Section: Foxm1 Is Overexpressed and Activated In Ovarian Cancermentioning

confidence: 99%

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

Liu

Barger

Karpf

2021

Cancers

View full text Add to dashboard Cite

Forkhead box M1 (FOXM1) is a member of the conserved forkhead box (FOX) transcription factor family. Over the last two decades, FOXM1 has emerged as a multifunctional oncoprotein and a robust biomarker of poor prognosis in many human malignancies. In this review article, we address the current knowledge regarding the mechanisms of regulation and oncogenic functions of FOXM1, particularly in the context of ovarian cancer. FOXM1 and its associated oncogenic transcriptional signature are enriched in >85% of ovarian cancer cases and FOXM1 expression and activity can be enhanced by a plethora of genomic, transcriptional, post-transcriptional, and post-translational mechanisms. As a master transcriptional regulator, FOXM1 promotes critical oncogenic phenotypes in ovarian cancer, including: (1) cell proliferation, (2) invasion and metastasis, (3) chemotherapy resistance, (4) cancer stem cell (CSC) properties, (5) genomic instability, and (6) altered cellular metabolism. We additionally discuss the evidence for FOXM1 as a cancer biomarker, describe the rationale for FOXM1 as a cancer therapeutic target, and provide an overview of therapeutic strategies used to target FOXM1 for cancer treatment.

show abstract

Section: Foxm1 Is Overexpressed and Activated In Ovarian Cancermentioning

confidence: 99%

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

Liu

Barger

Karpf

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Emerging research has revealed that the deregulation of lncRNAs plays a part in the occurrence and development of HCC. Many lncRNAs such as LINC01419 [ 16 ], MFI2-AS1 [ 17 ], and LINC00160 [ 18 ] have been reported to be upregulated in HCC. Consistent with these lncRNAs, FOXP4-AS1 was greatly overexpressed in HCC tissues and cells in this study.…”

Section: Discussionmentioning

confidence: 99%

Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma

Liang

Wang

Qiu

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Background. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer that has a high level of morbidity and mortality. Long noncoding RNA (lncRNA) is a novel regulatory factor of tumour proliferation, apoptosis, and metastasis. Our previous studies indicated that lncRNA FOXP4-AS1 is a functional oncogene in HCC; thus, this study is aimed at further evaluating the clinical and biological function of FOXP4-AS1 in HCC. Material and Methods. First, we detected the expression of FOXP4-AS1 in HCC tissues and paracarcinoma normal tissues by qRT-PCR. Second, the prognostic effects of FOXP4-AS1 in patients with HCC were analysed in a training group and a verification group. Subsequently, to investigate the biological effects of FOXP4-AS1 on HCC cells, downexpression tests were further conducted. Results. The expression of FOXP4-AS1 was higher in HCC tissues than adjacent nontumourous tissues, whereas the low expression of FOXP4-AS1 was correlated with optimistic treatment outcomes, which suggested that FOXP4-AS1 may be an independent prognostic biomarker for HCC. Moreover, the downregulation of FOXP4-AS1 significantly reduced the cell proliferation and clonal abilities and inhibited the invasion, migration, and angiogenesis of hepatoma cells ( P < 0.05 ). Conclusion. These results revealed the clinical significance and biological function of FOXP4-AS1 in HCC development, which may provide a new direction for finding therapeutic targets and potential prognostic biomarkers of HCC.

show abstract

“…There is increasing evidence that some lncRNAs are associated with the incidence and development of cancer. Multiple lncRNAs have been identified as playing a key role in HCC (Huang et al, 2020;Wei et al, 2020; FIGURE 5 | Knockdown of SNHG9 can inhibit the proliferation, migration, and invasion of HCC cells by upregulating GSTP1. (A) The expression of SNHG9 and GSTP1 after sgRNA-SNHG9 and SGI-1027 treatment and detected by RT-qPCR; (B) Western blot analysis of GSTP1 and DNMT after treatment with sg-SNHG9 and SGI-1027; (C) The proliferation of hepatocellular carcinoma cells treated with sgRNA-SNHG9, sgRNA-GSTP1, PCDNA-GSTP1, PCDNA-SNHG9, and PCDNA-GSTP1 + SNHG9 as detected by the CCK-8 method.…”

Section: Discussionmentioning

confidence: 99%

lncRNA SNHG9 Promotes Cell Proliferation, Migration, and Invasion in Human Hepatocellular Carcinoma Cells by Increasing GSTP1 Methylation, as Revealed by CRISPR-dCas9

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is among the major causes of cancer-related mortalities globally. Long non-coding RNAs (LncRNAs), as epigenetic molecules, contribute to malignant tumor incidences and development, including HCC. Although LncRNA SNHG9 is considered an oncogene in many cancers, the biological function and molecular mechanism of SNHG9 in HCC are still unclear. We investigated the effects of lncRNA SNHG9 on the methylation of glutathione S-transferase P1 (GSTP1) and the progression of HCC. Histological data analysis, CRISPR-dCas9, and cytological function experiment were used to study the expression level and biological function of SNHG9 in HCC. There was an upregulated expression of SNHG9 in HCC, which was associated with shorter disease-free survival. Knockdown of SNHG9 can inhibit cell proliferation, block cell cycle progression, and inhibit cell migration and invasion by upregulating GSTP1. LncRNA SNHG9 recruits methylated enzymes (DNMT1, DNMT3A, and DNMT3B) to increase GSTP1 promoter methylation, a common event in the development of HCC. Inhibition of lncRNA SNHG9 demethylates GSTP1, which prevents HCC progression, presents a promising therapeutic approach for HCC patients.

show abstract

LncRNA MFI2-AS1 promotes HCC progression and metastasis by acting as a competing endogenous RNA of miR-134 to upregulate FOXM1 expression

Cited by 33 publications

References 23 publications

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer

Long Noncoding RNA FOXP4-AS1 Predicts Unfavourable Prognosis and Regulates Proliferation and Invasion in Hepatocellular Carcinoma

lncRNA SNHG9 Promotes Cell Proliferation, Migration, and Invasion in Human Hepatocellular Carcinoma Cells by Increasing GSTP1 Methylation, as Revealed by CRISPR-dCas9

Contact Info

Product

Resources

About